Skip to content
ANAVEX
ANAVEXANAVEX
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • OUR TEAM
  • NEWS
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPIPELINEPressUncategorized

Low density of sigma-1 receptors in early Alzheimer’s disease.

ANAVEX 7-1037 Reduces Rate of Cancer Tumor Growth 69% in Pre-Clinical Studies, Compared to Currently Marketed Drug Dacarbazine Showing No Measurable Activity

Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008

Anavex Advances Drug Candidate for Treatment of Alzheimer’s Disease

Anavex Strengthens Board of Directors

ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors

Anavex Advances Drug Candidates for Treatment of Epilepsy

Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines.

Anti-amnesic and neuroprotective activities of ANAVEX 2-73, a new aminotetrahydrofuran derivative acting as a mixed muscarinic/sigma-1 ligands, in pharmacological and pathological models of amnesia.

Anavex Life Sciences Engages Primoris Group to Provide Investor Relations Services

1
23456789101112131415161718192021222324252627282930313233
…3435363738…
3940414243444546
47
ANAVEX

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top